LABORATORY DIAGNOSIS OF HEPATOCELLULAR CARCINOMA - CONVENTIONAL BIOMARKERS AND BLOOD PLASMA SPECTROSCOPY
نویسندگان
چکیده
HepatocelulĂĄrnĂ karcinom (HCC) je nejÄastÄjĹĄĂ primĂĄrnĂ zhoubnĂ˝ nĂĄdor jater, kterĂ˝ se ve vÄtĹĄinÄ pĹĂpadĹŻ rozvĂjĂ v terĂŠnu jaternĂ cirhĂłzy rĹŻznĂŠ etiologie. Jen ÄasnĂĄ stadia onemocnÄnĂ jsou indikovĂĄna k chirurgickĂŠ, potenciĂĄlnÄ kurativnĂ lĂŠÄbÄ. pĹibliĹžnÄ tĹetina HCC zachycena ÄasnĂ˝ch stadiĂch. ScreeningovĂ˝m vyĹĄetĹenĂm rizikovĂ˝ch skupin pacientĹŻ ultrasonografie jater (USG) 6mÄsĂÄnĂch intervalech. USG mĂĄ vedle svĂ˝ch znĂĄmĂ˝ch vĂ˝hod i znaÄnĂŠ limitace. Senzitivita pro pohybuje pouze okolo 60 %. Vzhledem tomu a proto, Ĺže jednĂĄ o expert dependentnĂ metodu, existuje nalĂŠhĂĄvĂĄ potĹeba objektivnĂho biomarkeru HCC. Alfa-fetoprotein obecnÄ vnĂmĂĄn jako biomarker HCC, nicmĂŠnÄ jeho senzitivita specificita ĂşÄely diagnostiky Äi dokonce screeningu nedostateÄnĂĄ. Byly zkoumĂĄny jinĂŠ dalĹĄĂ biomarkery s rĹŻznĂ˝mi vĂ˝sledky, ale ŞådnĂ˝ nedosĂĄhl efektivity USG. PomÄrnÄ novĂ˝m pĹĂstupem tĂŠto problematice spektroskopie krevnĂ plazmy, kterĂĄ prokĂĄzala svoji ĂşÄinnost u rĹŻznĂ˝ch onemocnÄnĂ. Z pohledu spektroskopii plazmy vÄnovalo jen mĂĄlo studiĂ. AutoĹi prezentujĂ pĹehledu vlastnĂ prĂĄci, kdy dosĂĄhla senzitivity specificity odliĹĄenĂ nemocnĂ˝ch cirhĂłzou bez nĂm 88 %, respektive 90 PĹes veĹĄkerĂŠ snahy nebyl dosud dostateÄnÄ spolehlivĂ˝ validovanĂ˝ pouĹžitelnĂ˝ ÄasnĂŠ identifikovĂĄn.
منابع مشابه
an overview of biomarkers for the diagnosis of hepatocellular carcinoma
context primary liver cancer is one of the most common and deadly malignant neoplasms worldwide. the incidence and mortality rates for hepatocellular carcinoma (hcc) are virtually identical, reflecting the poor overall survival of patients with this kind of tumor. effective therapies mostly achieved if the hcc diagnosis is made at early stages of the tumor. surveillance tests include serologic ...
متن کاملAn Overview of Biomarkers for the Diagnosis of Hepatocellular Carcinoma
CONTEXT Primary liver cancer is one of the most common and deadly malignant neoplasms worldwide. The incidence and mortality rates for hepatocellular carcinoma (HCC) are virtually identical, reflecting the poor overall survival of patients with this kind of tumor. Effective therapies mostly achieved if the HCC diagnosis is made at early stages of the tumor. Surveillance tests include serologic ...
متن کاملdiagnosis and staging of hepatocellular carcinoma
hepatocellular carcinoma (hcc) is the fifth most common tumor in the world, and its incidence is increasing. it is second most common cause of cancer related death worldwide and fastest growing cause of cancer death in the united states. cirrhosis is the most important clinical risk factor for hcc, with approximately 80% of cases of hcc developing in patients with a cirrhotic liver. hcc differs...
متن کاملPlasma miRNAs as early biomarkers for detecting hepatocellular carcinoma.
The early detection of hepatocellular carcinoma (HCC) presents a challenge because of the lack of specific biomarkers. Serum/plasma microRNAs (miRNAs) can discriminate HCC patients from controls. We aimed to identify and evaluate HCC-associated plasma miRNAs originating from the liver as early biomarkers for detecting HCC. In this multicenter three-phase study, we first performed screening usin...
متن کاملBiomarkers for Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide. The HCC diagnosis is usually achieved by biomarkers, which can also help in prognosis prediction. Furthermore, it might represent certain therapeutic interventions through some combinations of biomarkers. Here, we review on our current understanding of HCC biomarkers.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Vojenske? zdravotnicke? listy
سال: 2023
ISSN: ['0372-7025', '2571-113X']
DOI: https://doi.org/10.31482/mmsl.2022.046